This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PGCvax

GlaxoSmithKline plc

Drug Names(s): PGCvax

Description: PGCvax is a chimeric protein subunit vaccine based on two novel proteins fused in-frame, BVH-3 and BVH-11, found on the cell surface of pneumococci. These two proteins are found in strains from all 90 known pneumococcal serotypes, and the immune response to these proteins has been shown to be protective in preclinical models.

Deal Structure: GlaxoSmithKline acquired PGCvax through its acquisition of ID Biomedical. In September 2005, GlaxoSmithKline and ID Biomedical Corporation announced a definitive agreement for GSK to acquire ID Biomedical. In December 2005, ID Biomedical announced that the acquisition by GlaxoSmithKline closed and ID Biomedical is now a wholly-owned subsidiary of GSK.


PGCvax News

Pink Sheet Licensing In Brief


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug